- Home
- SOHU vs VCRE Comparison
SOHU vs VCRE Comparison
Compare SOHU & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOHU | VCRE |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | Sweden |
| Employees | N/A | 40 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 332.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOHU | VCRE |
|---|---|---|
| Price | $14.28 | $12.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 45.0K | 4.5K |
| Earning Date | 05-18-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $10.50 |
| 52 Week High | $17.30 | $13.00 |
Technical Indicators
Market Signals| Indicator | SOHU | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 46.02 |
| Support Level | $12.97 | $10.74 |
| Resistance Level | $14.83 | $12.93 |
| Average True Range (ATR) | 0.65 | 0.45 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 47.14 | 60.69 |
Price Performance
Historical ComparisonAbout SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.